title: Adjuvant activity mediated by iNKT cells.
abstract: Invariant natural killer T (iNKT) cells have adjuvant activity due to their ability to produce large amounts of IFN-gamma, which activates other cells in innate and acquired systems, and orchestrates protective immunity. Based on these adjuvant mechanisms, we developed iNKT cell-targeted adjuvant therapy and carried out a phase I/IIa trial on advanced lung cancer patients. The patient group with increased numbers of IFN-gamma-producing cells showed prolonged survival with a median survival time of 31.9 months. Sixty percent of the patients in this group survived for more than 2 years with only a primary treatment and without tumor progression and metastasis.
authors: Research Unit for Cellular Immunotherapy, RIKEN Research Center for Allergy and Immunology, 1-7-22, Suehiro-cho, Tsurumi-ku, Yokohama, Japan.
authors: Shinichiro
authors: S
authors: Fujii
authors: Shinichiro
authors: S
authors: Motohashi
authors: Kanako
authors: K
authors: Shimizu
authors: Toshinori
authors: T
authors: Nakayama
authors: Yohei
authors: Y
authors: Yoshiga
authors: Masaru
authors: M
authors: Taniguchi
mesh_terms: D056704:Adaptive Immunity; D000276:Adjuvants, Immunologic; D000818:Animals; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D005699:Galactosylceramides / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007113:Immunity, Innate; D007167:Immunotherapy; D007371:Interferon-gamma / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D055611:Natural Killer T-Cells / Q000276:immunology*; D009362:Neoplasm Metastasis
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D005699:Galactosylceramides; C493154:alpha-galactosylceramide; D007371:Interferon-gamma